{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:11:46Z","timestamp":1789762306553,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coi.2026.102841","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:43:28Z","timestamp":1789760608000},"page":"102841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing evidence generation in pediatric rheumatology beyond traditional randomized clinical trials: the potential of innovative designs"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0645-1163","authenticated-orcid":false,"given":"Alessandra","family":"Alongi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Risca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"La Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102841_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coi.2026.102841_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40272-017-0244-2","article-title":"Clinical trial design in juvenile idiopathic arthritis","volume":"19","author":"Balevic","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.coi.2026.102841_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib4","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/art.27670","article-title":"Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102841_bib5","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(24)00026-2","article-title":"How can trial designs better serve the needs of children and young people with juvenile idiopathic arthritis?","volume":"6","author":"Feilding","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/acr.25482","article-title":"25 years of biologics for the treatment of pediatric rheumatic disease: advances in prognosis and ongoing challenges","volume":"77","author":"Shishov","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102841_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102841_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.conctc.2018.08.009","article-title":"Master protocol trials in oncology: review and new trial designs","volume":"12","author":"Hirakawa","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.coi.2026.102841_bib9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.seminoncol.2015.07.009","article-title":"The master protocol concept","volume":"42","author":"Redman","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.coi.2026.102841_sbref10","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-21-5496","article-title":"Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases","volume":"10","author":"Li","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.coi.2026.102841_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/19466315.2021.1906743","article-title":"Type I error considerations in master protocols with common control in oncology trials: report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion","volume":"14","author":"Sridhara","year":"2022","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.coi.2026.102841_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/cancers16020251","article-title":"Bayesian methods for information borrowing in basket trials: an overview","volume":"16","author":"Zhou","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.coi.2026.102841_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103172","article-title":"The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial","volume":"144","author":"Lorenzon","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102841_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089827","article-title":"Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Beh\u00e7et\u2019s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol","volume":"15","author":"Geertsema-Hoeve","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.coi.2026.102841_sbref15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2026.102841_bib16","article-title":"Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy","volume":"16","author":"Liang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102841_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.rdc.2025.05.002","article-title":"The challenges of new biologic therapies in pediatrics: an update on the limited therapeutic options for juvenile psoriatic arthritis","volume":"51","author":"Costello","year":"2025","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.coi.2026.102841_bib18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/rheumatology\/keab696","article-title":"Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised phase 3 CLUSTER trial","volume":"61","author":"Jeyaratnam","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102841_bib19","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102841_bib21","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1093\/rheumatology\/keae392","article-title":"Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis","volume":"63","author":"Papadopoulou","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102841_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12969-025-01107-1","article-title":"Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis","volume":"23","author":"Ramanan","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.coi.2026.102841_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/09612033251349930","article-title":"Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States","volume":"34","author":"Pottackal","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102841_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12969-023-00867-y","article-title":"The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?","volume":"21","author":"Canna","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.coi.2026.102841_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2025.105872","article-title":"Systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease are the same disease and should now be designated by the same unique name, Still\u2019s disease","volume":"92","author":"Mitrovic","year":"2025","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.coi.2026.102841_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-024-01184-8","article-title":"Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus","volume":"21","author":"Goldbach-Mansky","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib27","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/rheumatology\/keae269","article-title":"ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials","volume":"63","author":"Arnold","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102841_bib28","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.21.02285","article-title":"Basket trials: review of current practice and innovations for future trials","volume":"40","author":"Hobbs","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2026.102841_bib29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/bimj.202000314","article-title":"Categories, components, and techniques in a modular construction of basket trials for application and further research","volume":"63","author":"Pohl","year":"2021","journal-title":"Biom J"},{"key":"10.1016\/j.coi.2026.102841_bib30","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2026.102841_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1037439","article-title":"Design and analysis of umbrella trials: where do we stand?","volume":"9","author":"Ouma","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2026.102841_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adt6050","article-title":"Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity","volume":"17","author":"Bolton","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2026.102841_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cct.2017.01.003","article-title":"Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials","volume":"54","author":"Lin","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.coi.2026.102841_sbref34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102384","article-title":"Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL","volume":"67","author":"Koenig","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.coi.2026.102841_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/216847900604000412","article-title":"Adaptive seamless phase II\/III designs: background, operational aspects, and examples","volume":"40","author":"Maca","year":"2006","journal-title":"Drug Inf J"},{"key":"10.1016\/j.coi.2026.102841_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5694\/mja2.52711","article-title":"Platform trials: key features, when to use them and methodological challenges","volume":"223","author":"Mahar","year":"2025","journal-title":"Med J Aust"},{"key":"10.1016\/j.coi.2026.102841_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2026.107384","article-title":"Design and rationale of RECOVER-AUTONOMIC: a randomized platform trial evaluating interventions for Long COVID postural orthostatic tachycardia syndrome","author":"Fudim","year":"2026","journal-title":"Am Heart J"},{"key":"10.1016\/j.coi.2026.102841_bib38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13063-024-08156-z","article-title":"RECOVER-NEURO: study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC)","volume":"25","author":"Knopman","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.coi.2026.102841_sbref39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41575-025-01052-0","article-title":"Developing an adaptive platform trial for evaluation of medical treatments for Crohn\u2019s disease","volume":"22","author":"Noor","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2026.102841_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cgh.2024.06.036","article-title":"The future of clinical trials in inflammatory bowel disease","volume":"23","author":"Ma","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coi.2026.102841_bib41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Adaptive Platform Trials Coalition","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coi.2026.102841_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s41927-025-00563-2","article-title":"Use of Bayesian techniques in clinical trials for rheumatoid arthritis and systemic sclerosis: a scoping review","volume":"9","author":"Churipuy","year":"2025","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib43","article-title":"Regulatory expectations for Bayesian methods in drug and biologic clinical trials: a practical perspective on FDA\u2019s 2026 draft guidance","author":"Ji","year":"2026","journal-title":"arXiv"},{"key":"10.1016\/j.coi.2026.102841_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1177\/09622802251348183","article-title":"Response adaptive randomisation in clinical trials: current practice, gaps and future directions","volume":"34","author":"Wilson","year":"2025","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.coi.2026.102841_bib45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12874-025-02693-0","article-title":"Randomization in the age of platform trials: unexplored challenges and some potential solutions","volume":"25","author":"Kuznetsova","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.coi.2026.102841_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.70059","article-title":"Statistical modeling to adjust for time trends in adaptive platform trials utilizing non-concurrent controls","volume":"67","author":"Krotka","year":"2025","journal-title":"Biom J"},{"key":"10.1016\/j.coi.2026.102841_bib47","first-page":"1","article-title":"Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT)","author":"Bardgett","year":"2025","journal-title":"Effic Mech Eval"},{"key":"10.1016\/j.coi.2026.102841_bib48","first-page":"1823","article-title":"Clinical predictors of remission in systemic juvenile idiopathic arthritis\/Still\u2019s disease: insight from real-life data and the potential relevance of the \u201cwindow of opportunity","volume":"43","author":"Abu-Rumeileh","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102841_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/acr.25459","article-title":"Transcriptional profiling of tofacitinib treatment in juvenile idiopathic arthritis: implications for treatment response prediction","volume":"77","author":"Eloseily","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102841_bib50","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kex206","article-title":"Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate","volume":"56","author":"Moncrieffe","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102841_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-statistics-022513-115553","article-title":"Dynamic treatment regimes","volume":"1","author":"Chakraborty","year":"2014","journal-title":"Annu Rev Stat Appl"},{"key":"10.1016\/j.coi.2026.102841_bib52","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/19466315.2022.2118162","article-title":"Comparing dose levels to placebo using a continuous outcome in a small n, sequential, multiple assignment, randomized trial (snSMART)","volume":"15","author":"Fang","year":"2023","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.coi.2026.102841_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2023.101060","article-title":"Multisystem inflammatory syndrome therapies in children (MISTIC): a randomized trial","volume":"32","author":"Jain","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.coi.2026.102841_sbref54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10543406.2023.2292206","article-title":"Addressing sequential and concurrent treatment regimens in a small n sequential, multiple assignment, randomized trial (snSMART) in the MISTIC study","volume":"35","author":"Cheng","year":"2025","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.coi.2026.102841_bib55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102841_bib56","article-title":"Recent innovations in adaptive trial designs: a review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J Clin Transl Sci"},{"key":"10.1016\/j.coi.2026.102841_bib57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/10543406.2023.2275765","article-title":"Adaptive platform trials: the impact of common controls on type one error and power","volume":"34","author":"Nguyen","year":"2024","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.coi.2026.102841_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag263","article-title":"Evaluating the efficiency of platform trials relative to stand-alone trials: a simulation study for the evaluation of new antibacterials","volume":"81","author":"Hardy","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coi.2026.102841_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs conventional trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:43:35Z","timestamp":1789760615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526001184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S0952791526001184"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102841","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing evidence generation in pediatric rheumatology beyond traditional randomized clinical trials: the potential of innovative designs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102841"}}